ESMO Advanced Course on Breast Cancer: Filling the Gaps Following Progression on CDK4/6 in Hormone Receptor Positive HER2 Negative Advanced Breast Cancer 2024: Doha

Learning objectives

• Understanding the function and biology of CDK4/6 in breast cancer
• Information and in-depth discussion on the state of the art and emerging therapeutic strategies integrating CDK4/6 inhibition in breast cancer, both in the early and metastatic setting
• Assessing the clinical and genomic features for risk of relapse in early HR+/HER2 negative breast cancer
• Presenting novel data on biomarkers of benefit, mechanisms of resistance and combinatorial therapeutic strategies of CDK4/6 inhibition
• Discussing clinical cancer cases to integrate use of CDK4/6 inhibitors in clinical practice

Download the programme

Co-Chairs:

• Nadia Harbeck, Germany
• Salha Bujassoum, Qatar

Accreditation

The programme of this event has been accredited with 7 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to ESMO-MORA Recertification Process & Requirements.